These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 1616831)

  • 41. Autoantibody stabilization of the classical pathway C3 convertase leading to C3 deficiency and Neisserial sepsis: C4 nephritic factor revisited.
    Miller EC; Chase NM; Densen P; Hintermeyer MK; Casper JT; Atkinson JP
    Clin Immunol; 2012 Dec; 145(3):241-50. PubMed ID: 23117396
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hypocomplementemic proliferative glomerulonephritis with C3 nephritic-factor-like activity in multiple myeloma.
    Bourke E; Campbell WG; Piper M; Check IJ
    Nephron; 1989; 52(3):231-7. PubMed ID: 2662048
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Partial lipodystrophy and membranoproliferative glomerulonephritis. Apropos of a case].
    Martínez Debora MJ; Vázquez Martul M; Ecija Peiró JL; González Pérez J; Lirio Rodríguez J; González Mediero I
    An Esp Pediatr; 1989 Jun; 30(6):499-502. PubMed ID: 2679278
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Paramesangial glomerular deposits in membranoproliferative glomerulonephritis type II correlate with hypocomplementemia.
    West CD; McAdams AJ
    Am J Kidney Dis; 1995 Jun; 25(6):853-61. PubMed ID: 7771481
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Partial lipodystrophy, mesangiocapillary glomerulonephritis, and complement dysregulation. An autoimmune phenomenon.
    Levy Y; George J; Yona E; Shoenfeld Y
    Immunol Res; 1998 Aug; 18(1):55-60. PubMed ID: 9724849
    [TBL] [Abstract][Full Text] [Related]  

  • 46. C3 glomerulopathy: A new complement-based entity.
    de Lorenzo A; Tallón S; Hernández-Sevillano B; de Arriba G
    Rev Clin Esp (Barc); 2014; 214(5):266-74. PubMed ID: 24576419
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Partial lipodystrophy, C3 nephritic factor and clinically inapparent mesangiocapillary glomerulonephritis.
    Bennett WM; Bardana EJ; Wuepper K; Houghton D; Border WA; Götze O; Schreiber R
    Am J Med; 1977 May; 62(5):757-60. PubMed ID: 860726
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Differences between membranoproliferative glomerulonephritis types I and III in clinical presentation, glomerular morphology, and complement perturbation.
    Jackson EC; McAdams AJ; Strife CF; Forristal J; Welch TR; West CD
    Am J Kidney Dis; 1987 Feb; 9(2):115-20. PubMed ID: 3826060
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Biological significance of the C3 nephritic factor in membranoproliferative glomerulonephritis.
    Schena FP; Pertosa G; Stanziale P; Vox E; Pecoraro C; Andreucci VE
    Clin Nephrol; 1982 Nov; 18(5):240-6. PubMed ID: 7151338
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Streptococcal infection as possible trigger for dense deposit disease (C3 glomerulopathy).
    Prasto J; Kaplan BS; Russo P; Chan E; Smith RJ; Meyers KE
    Eur J Pediatr; 2014 Jun; 173(6):767-72. PubMed ID: 24384791
    [TBL] [Abstract][Full Text] [Related]  

  • 51. C3 nephritic factor in a patient with recurrent Neisseria meningitidis infections.
    Teisner B; Elling P; Svehag SE; Poulsen L; Lamm LU; Sjöholm A
    Acta Pathol Microbiol Immunol Scand C; 1984 Dec; 92(6):341-9. PubMed ID: 6570081
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Complement activation in acute glomerulonephritis in children.
    Levy M; Sich M; Pirotzky E; Habib R
    Int J Pediatr Nephrol; 1985; 6(1):17-24. PubMed ID: 3997368
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Persistently circulating C3 nephritic factor (C3 NeF)-stabilized alternative pathway C3 convertase (C3 CoF) in serum of an 11-year-old girl with meningococcal septicemia--simultaneous occurrence with free C3 NeF.
    Wahn V; Müller W; Rieger C; Rother U
    Pediatr Res; 1987 Aug; 22(2):123-9. PubMed ID: 3658535
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Idiopathic mesangiocapillary glomerulonephritis. Comparison of types I and II in children and adults and long-term prognosis.
    Cameron JS; Turner DR; Heaton J; Williams DG; Ogg CS; Chantler C; Haycock GB; Hicks J
    Am J Med; 1983 Feb; 74(2):175-92. PubMed ID: 6337487
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Recurrent bacterial infections associated with C3 nephritic factor and hypocomplementemia.
    Edwards KM; Alford R; Gewurz H; Mold C
    N Engl J Med; 1983 May; 308(19):1138-41. PubMed ID: 6835339
    [No Abstract]   [Full Text] [Related]  

  • 56. Patterns of complement activation in idiopathic membranoproliferative glomerulonephritis, types I, II, and III.
    Varade WS; Forristal J; West CD
    Am J Kidney Dis; 1990 Sep; 16(3):196-206. PubMed ID: 2205097
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Factor I deficiency and C3 nephritic factor: immunochemical findings and association with Neisseria meningitidis infection in two patients.
    Teisner B; Brandslund I; Folkersen J; Rasmussen JM; Poulsen LO; Svehag SE
    Scand J Immunol; 1984 Oct; 20(4):291-7. PubMed ID: 6239368
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Selective disappearance of C3NeF IgG autoantibody in the plasma of a patient with membranoproliferative glomerulonephritis following renal transplantation.
    Frémeaux-Bacchi V; Weiss L; Brun P; Kazatchkine MD
    Nephrol Dial Transplant; 1994; 9(7):811-4. PubMed ID: 7970124
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mesangiocapillary glomerulonephritis and persistent hypocomplementemia.
    Cameron JS; Ogg CS; Turner DR; Weller RO; White RH; Glasgow EF; Peters DK; Martin A
    Perspect Nephrol Hypertens; 1973; 1 Pt 1():541-56. PubMed ID: 4220250
    [No Abstract]   [Full Text] [Related]  

  • 60. Analysis of C3 Nephritic Factors by ELISA.
    Skattum L
    Methods Mol Biol; 2019; 1901():177-182. PubMed ID: 30539576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.